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Foxo Transcription Factors Induce
the Atrophy-Related Ubiquitin Ligase Atrogin-1
and Cause Skeletal Muscle Atrophy
et al., 2001). mRNA for atrogin-1 increases 8–40-fold in
all types of atrophy studied, and this increase precedes
the onset of muscle weight loss. Moreover, knockout
animals lacking atrogin-1 show a reduced rate of muscle
atrophy after denervation (Bodine et al., 2001a).
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Since various types of atrophy share a common setHarvard Medical School
of transcriptional adaptations, it seems likely that theBoston, Massachusetts 02115
diverse stimuli triggering atrophy act through common2 Department of Biomedical Sciences
signaling mechanisms and influence the same transcrip-Venetian Institute of Molecular Medicine
tion factor(s). Low levels of insulin and probably IGF-1,35129 Padova
together with elevated levels of glucocorticoids, triggerItaly
the loss of muscle protein after food deprivation and in3Renal Unit
diabetes (Mitch et al., 1999), and insulin resistance is aBeth Israel Deaconess Medical Center
characteristic feature of many systemic diseases thatBoston, Massachusetts 02215
appears to contribute to muscle wasting. Glucocorti-4 Boston University Medical School
coids are necessary for the activation of proteolysis inCardiovascular Research Institute
fasting, diabetes, and sepsis, and in large doses byBoston, Massachusetts 02118
themselves cause muscle wasting (Hasselgren, 1999).
However, the signal transduction pathways by which
glucocorticoids and low insulin trigger muscle proteinSummary
loss have not been defined.
In addition to stimulating myoblast fusion to form myo-Skeletal muscle atrophy is a debilitating response to
tubes during embryogenesis, IGF-1 and insulin promotefasting, disuse, cancer, and other systemic diseases.
net protein accumulation (i.e., hypertrophy) of matureIn atrophying muscles, the ubiquitin ligase, atrogin-1
myotubes and adult muscle fibers. In skeletal muscle,(MAFbx), is dramatically induced, and this response is
the binding of IGF-1 or insulin activates two major signal-necessary for rapid atrophy. Here, we show that in
ing pathways: the Ras-Raf-MEK-ERK pathway and thecultured myotubes undergoing atrophy, the activity of
PI3K/AKT pathway. The Ras-Raf-MEK-ERK pathway af-the PI3K/AKT pathway decreases, leading to activa-
fects fiber type composition but has no effect on muscletion of Foxo transcription factors and atrogin-1 induc-
fiber size (Murgia et al., 2000), while activation of thetion. IGF-1 treatment or AKT overexpression inhibits
PI3K/AKT pathway induces muscle hypertrophy appar-Foxo and atrogin-1 expression. Moreover, constitu-
ently by stimulating translation via regulation of GSKtively active Foxo3 acts on the atrogin-1 promoter to
and mTOR kinases (Bodine et al., 2001b). In addition tocause atrogin-1 transcription and dramatic atrophy of
its activation by insulin and AKT, mTOR is controlled bymyotubes and muscle fibers. When Foxo activation is
the supply of amino acids and glucose (Kim et al., 2003).blocked by a dominant-negative construct in myo-
Low levels of amino acids lead to inhibition of mTORtubes or by RNAi in mouse muscles in vivo, atrogin-1
and S6K and during fasting, the fall in insulin and IGF-1induction during starvation and atrophy of myotubes
decrease nutrient transport into muscle, which mustinduced by glucocorticoids are prevented. Thus, fork-
further reduce mTOR activity. mTOR can thus integrate
head factor(s) play a critical role in the development
signals from the IGF-1/PI3K/AKT pathway with informa-
of muscle atrophy, and inhibition of Foxo factors is an
tion about the cell’s nutritional status, both of which
attractive approach to combat muscle wasting. influence mTOR activity.
Several recent findings suggest that decreased activ-
Introduction ity of the IGF-1/PI3K/AKT signaling pathway can lead
to muscle atrophy (Bodine et al., 2001b). Inhibition of
Muscle atrophy occurs systemically in fasting and a PI3K and expression of a dominant-negative AKT reduce
variety of diseases (e.g., cancer, diabetes mellitus, AIDS, the mean size of myotubes in culture (Rommel et al.,
sepsis, and Cushing’s Syndrome) and in specific mus- 2001). Muscles from mice lacking Akt1 and Akt2 are
cles upon denervation or disuse (Lecker et al., 1999). In small (Peng et al., 2003). Conversely, activation of AKT
these diverse conditions, the atrophying muscles show in rat muscle can prevent denervation atrophy (Pallafac-
increased rates of protein degradation primarily through china et al., 2002; Bodine et al., 2001b). Much of the
activation of the ubiquitin-proteasome pathway (Jagoe growth promotion by IGF-1, insulin, and activated AKT
and Goldberg, 2001) and a common series of transcrip- results from a general increase in protein synthesis, and
tional adaptations that together constitute an “atrophy reduced AKT activity probably causes the decrease in
program” (Jagoe et al., 2002; Lecker et al., 2004). The protein translation seen in many types of muscle atro-
protein induced most dramatically during atrophy is the phy. However, in related studies, using glucocorticoid-
muscle-specific Ub-ligase, atrogin-1 (MAFbx) (Gomes treated myotubes as a simple in vitro model of muscle
atrophy, we showed that dexamethasone (Dex) in-
creases protein degradation and atrogin-1 expression,*Correspondence: slecker@bidmc.harvard.edu (S.H.L.), alfred_
and these responses could be rapidly suppressed bygoldberg@hms.harvard.edu (A.L.G.)
5These authors contributed equally to this work. IGF-1 or insulin (Sacheck et al., 2004). Moreover, inhibi-
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Figure 1. Starving Cells and Glucocorticoid Treatment Induce atrogin-1 Expression and Dephosphorylation of Members of the PI3K/AKT-Signal-
ing Pathway
(A and B) C2C12 myotubes were starved by removal of growth medium and incubated in PBS for 6 hr. Medium was replaced in refed samples for
12 hr.
(A) Effect of starvation on atrogin-1 expression: Northern blots probed for atrogin-1 and GAPDH (middle image) and fold increase in atrogin-1
mRNA, calculated by dividing the atrogin-1 band intensity (atrogin-1/GADPH) with the atrogin-1/GADPH ratio in the control condition (upper image).
Both atrogin-1 bands were used in the analysis. Micrographs of representative control, starved, and refed C2C12 myotube cultures (lower image).
(B) Effect of starvation on components of the PI3K/AKT pathway: proteins were extracted from the same samples as in a, and subjected to
immunoblot analysis. Quantitation of the ratio of phosphorylated to total protein was determined as above. Data was normalized to a control of 100%.
(C) Effect of 1 M Dex treatment on atrogin-1 expression.
(D) Effect of Dex on PI3K/AKT pathway components.
Foxo and Muscle Atrophy
401
tors of PI3K stimulated protein degradation and expres- rapid muscle wasting and an 8–10-fold increase in
atrogin-1 mRNA (Gomes et al., 2001), we studied thesion of atrogin-1 in these myotubes. These experiments
strongly suggest that the IGF-1/PI3K/AKT pathway, in effects of starving cultured myotubes of serum, glucose,
and amino acids. After 6 hr, these myotubes showed aaddition to affecting translational initiation, suppresses
protein degradation, especially of myofibrillar proteins, 60% decrease in diameter (Figure 1A), and contained
2.5-fold more atrogin-1 mRNA than control cells (Figureand expression of atrogin-1.
One downstream target of the PI3K/AKT pathway that 1A). These changes were completely reversed by resup-
plying serum and nutrients for 12 hr (Figure 1A). In relatedcould mediate these IGF-1 effects is the Forkhead box
O (Foxo) class of transcription factors, a subfamily of studies, we found that treatment of differentiated myo-
tubes with the glucocorticoid, dexamethasone (Dex) in-the large group of forkhead transcription factors. Mam-
malian cells contain three members of this family, Foxo1 duced atrogin-1, stimulated breakdown of myofibrillar
proteins, and caused a loss of protein and RNA content(FKHR), Foxo3 (FKHRL1), and Foxo4 (AFX) (Tran et al.,
2003). AKT blocks the function of all three by phosphory- (Sacheck et al., 2004). After 24 hr treatment with Dex,
there was a 2–3-fold increase in atrogin-1 mRNA (Figurelation of three conserved residues, leading to their se-
questration in the cytoplasm away from target genes 1C) and a 40% reduction in mean myotube diameter
(see Figure 3D).(Brunet et al., 1999). Dephosphorylation of Foxo factors
leads to nuclear entry and growth suppression or apo- Since these rapid responses mimic the major features
of atrophy in vivo and since inhibition of the PI3K/AKT/ptosis (Ramaswamy et al., 2002). Foxo gene expression
is also tightly regulated. Fasting and glucocorticoids mTOR pathway can induce muscle wasting (Bodine et
al., 2001b), we tested whether the phosphorylation ofinduce the expression of Foxo factors in mouse liver and
muscle, while refeeding suppresses Foxo transcription components of this pathway change upon Dex treat-
ment for 24 hr or deprivation of serum and nutrients for(Furuyama et al., 2003; Imae et al., 2003). Foxo factors
are also necessary for the development of insulin resis- 6 hr. Both these treatments reduced levels of phosphor-
ylated AKT below levels in control cultures, as revealedtance in type II diabetes (Nakae et al., 2002; Puigserver
et al., 2003). Furthermore, we found recently that Foxo1 by immunoblot and densitometric analysis of the ratio
of phospho-AKT to total AKT (Figures 1B and 1D). Densi-is an atrophy-related gene (“atrogene”) that is induced
in many, perhaps all, types of muscle atrophy (Lecker et tometric analysis revealed that the ratio of phospho-
AKT to total AKT fell consistently when atrogin-1al., 2004). These atrophy-related genes (formerly termed
“atrogins”) are here called “atrogenes” to prevent confu- mRNA increased.
A reduction in AKT activity would be expected to leadsion with the ubiquitin-ligase, atrogin-1.
We have used two simple in vitro models of muscle to decreased phosphorylation of Foxo1, 3, and Foxo4
and in fact, the levels of phosphorylated Foxo1 andatrophy, cell starvation, and treatment with the synthetic
glucocorticoid, dexamethasone, to identify the down- 3 decreased in the starved and Dex-treated cultures.
Forkhead factors shuttle between the nucleus and cyto-stream targets of the IGF1/PI3K/AKT pathway that are
important for the induction of atrogin-1 and the develop- plasm and when phosphorylated, are sequestered in
the cytoplasm in association with 14-3-3 proteins. Wement of muscle wasting. We demonstrate that IGF-1
acts through AKT and Foxo to suppress atrogin-1 tran- measured the amount of Foxo in nuclear extracts of
myotubes after starvation. A marked increase in nuclearscription, and that the mTOR/S6K, GSK, and NFB path-
ways are not important in regulating atrogin-1 expres- Foxo1 and Foxo3 content was seen after starvation for
2 hr (Figure 1E, left image). To test if these nuclearsion. Further studies show that Foxo3 activation also
causes transcription of the atrogin-1 promoter and a Foxo species had DNA binding activity, we used an
electrophoretic mobility shift assay (Figure 1E, right im-dramatic decrease in fiber size. Our surprising discovery
of the key role of Foxo in triggering the atrophy program age). Factors in the nuclear extract from starved (but
not control) myotubes bound to an oligonucleotide con-should lay the basis not only for further understanding
of the mechanisms of muscle wasting in diverse dis- taining a known forkhead binding site. A 100-fold molar
excess of this unlabeled oligonucleotide (competitor)eases, but also for developing novel therapies for these
debilitating conditions. prevented formation of the complex, but an unrelated
oligonucleotide (non competitor) containing an SP1
binding site did not. In addition, we analyzed the sameResults
nuclear extracts with oligonucleotides containing bind-
ing sites for NFB, AP1, and CREB. Unlike the FoxoActivity of the PI3K/AKT Pathway Decreases
in Myotubes Undergoing Atrophy factors, neither NFB, AP1, nor CREB, showed more
binding activity in the starved extract. Together, theseTo identify the signaling pathway(s) that activate atro-
gin-1 expression during atrophy, we defined the changes data strongly suggest that Foxo factors are activated
by dephosphorylation and nuclear entry in the atrophy-in atrogin-1 mRNA content and the phosphorylation lev-
els of intermediates in the PI3K/AKT pathway in two ing myotubes.
Since S6K activity is modulated by both AKT and theexperimental conditions that we found induce atrophy
of C2C12 myotubes. Since food deprivation leads to nutrient-sensitive mTOR/RAPTOR/GßL complex (Kim et
(E) Foxo factors are nuclear in starved C2C12 myotubes. Left image: nuclear extracts from control and starved myotubes were immunoblotted
with anti-Foxo antibodies. Right image: nuclear extracts were tested for binding to double-stranded 32P-labeled oligonucleotides containing Foxo,
CREB, NFB, and AP1 binding sites by electrophoretic mobility shift assay. Arrow, Foxo–oligonucleotide complexes. Asterix, nonspecific band.
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Figure 2. IGF-1 and AKT Block the Induction
of atrogin-1 by Starvation and Dex Treatment
and Cause Foxo Phosphorylation
(A) Myotubes were incubated in the absence
or presence of IGF-1 (10 ng/ml) and concomi-
tantly starved (for 6 hr) or treated with Dex (for
24 hr). Northern blots were performed for
atrogin-1 expression (upper image) and the
amount and phosphorylation of AKT pathway
members assayed by immunoblot (lower im-
age) as in Figure 1.
(B) Myotubes were infected with adenoviral
vectors for c.a. AKT, d.n. AKT, or with control
virus (gal). 36 hr after infection, half the myo-
tubes were treated with 1 M Dex for 24
hr, and atrogin-1 expression analyzed by
Northern.
(C) Immunoblots for AKT and its downstream
targets in the cultures from (B), overexpressed
proteins were detected by anti-HA immu-
noblot.
al., 2003), the removal of serum and nutrients led to an IGF-1 addition, while in the Dex-treated cultures, IGF-1
restored S6K phosphorylation. Thus, S6K is unlikely toalmost complete dephosphorylation of S6K (Figure 1B).
The readdition of cell culture medium to the starved cells be regulating atrogin-1 expression.
To test directly whether IGF-1 suppresses atrogin-1increased the phosphorylation of AKT, Foxo factors, and
S6K and decreased atrogin-1 mRNA to control levels. expression through its effect on AKT, we used adenovi-
ral vectors to introduce into myotubes a constitutivelyAlthough S6K was markedly dephosphorylated in the
starved cells, after Dex treatment, the level of phosphor- active (c.a.) AKT and dominant-negative (d.n.) form of
AKT (Skurk et al., 2004). Like IGF-1 treatment, expres-ylated S6K decreased only slightly (Figure 1D). Thus, in
these two conditions, the dephosphorylation of Foxo sion of c.a. AKT prevented atrogin-1 induction by Dex
(Figure 2B) and blocked the reduction in phosphoryla-factors, but not of S6K, correlated with atrogin-1 in-
duction. tion of Foxo1, 3, and 4 (Figure 2C). On the other hand,
expression of d.n. AKT slightly enhanced the Dex-
dependent induction of atrogin-1 (Figure 2B) and didAtrogin-1 Expression Is Suppressed by IGF-1
through the PI3K/AKT Pathway not affect the dephosphorylation of the forkhead tran-
scription factors (Figure 2C). These findings further sup-To learn if activation of the PI3K/AKT pathway sup-
presses expression of atrogin-1, we measured whether port the involvement of PI3K, AKT, and Foxo factors in
mediating the effects of IGF-1 on atrogin-1 expression.the addition of IGF-1 could prevent dephosphorylation
of AKT and Foxo1, 3, and 4 and block the high level of
atrogin-1 expression in both starved and Dex-treated Foxo3 Dephosphorylation Activates
the atrogin-1 Promotercells. Indeed, addition of IGF-1 to either model of atro-
phy suppressed atrogin-1 mRNA to the level in untreated To further explore the involvement of Foxo factors in
atrogin-1 regulation, we utilized adenoviral constructsmyotubes (Figure 2A) and increased the levels of phos-
phorylated Foxo1, 3, and 4. However, in the starved that express wild-type Foxo3 (FOXO3A) or used a
constitutively active form (c.a.FOXO3A) that is mutatedcells, S6K remained largely dephosphorylated after
Foxo and Muscle Atrophy
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Figure 3. Foxo3 Induces atrogin-1 Expression and Causes Reduction in Myotube Size
(A) Foxo3 induces atrogin-1 expression. Myotubes were infected with adenoviral vectors for FOXO3A and c.a. FOXO3A in the absence or presence
of IGF-1 (10 ng/ml) and after 48 hr, atrogin-1 mRNA levels were assayed and depicted as in Figure 1. Overexpressed proteins were detected by
anti-HA immunoblot.
(B) The atrogin-1 promoter is activated by Foxo3. Myoblasts were transfected with the atrogin-1 reporter constructs 1.0AT1 or 3.5AT1, differentiated
for four days, and then infected with FOXO3A or with a control (GFP) vector for 24 hr. Extracts were assayed for Firefly and Renilla luciferase
activity. Firefly/Renilla activity was normalized to 1.0 in the control (GFP) infection.
(C) Fluorescence microscopy of myotube cultures overexpressing Foxo3. Myotube cultures were infected with control adenovirus (GFP) or c.a.
FOXO3A and photographed 48 hr after infection. Mean myotube diameter from each culture was quantified from three independent experiments.
(D) D.n. Foxo3 inhibits dex-induced atrogin-1 expression and reduction in myotube diameter. Myotubes were infected with adenoviral vectors
expressing d.n. FOXO3A, c.a. FOXO3A, or GFP, and incubated in the absence or presence of 1 M Dex for 24 hr. Overexpressed d.n. FOXO3A
was detected by anti-HA immunoblot. Left image: Northern analysis of atrogin-1 expression. Middle image: fluorescence microscopy of myotube
cultures after 48 hr. Right image: quantification of mean myotube diameters in the presence of Dex and Foxo expression.
at the three AKT phosphorylation sites, T32A, S253A, tively active mutant both caused a large increase in
atrogin-1 mRNA (Figure 3A). The addition of IGF-1 to theand S315A (Brunet et al., 1999). Each construct also
expressed GFP, which enabled us to measure the effi- cells expressing the Foxo3 reduced sharply atrogin-1
mRNA content, presumably because IGF-1 inducedciency of infection and to follow the morphological
changes in the myotubes that result from expression of AKT-mediated phosphorylation and inactivation of the
wild-type Foxo3. Accordingly, IGF-1 addition did notactive Foxo3. In the myotubes, Foxo3 and the constitu-
Cell
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Figure 4. Foxo3, but Not Other AKT Targets,
Activates atrogin-1 Expression
(A) Myotubes were infected with various ade-
noviral vectors for 48 hr and then atrogin-1 ex-
pression was analyzed (upper image). Over-
expressed proteins were detected by anti-HA
immunoblots (lower image).
(B) Myoblasts were transfected with 3.5AT1,
differentiated, and infected with the indicated
vectors. Luciferase activity in extracts from
these cultures was analyzed as in Figure 3B.
Results are normalized to the control GFP in-
fection.
reduce the high level of atrogin-1 mRNA in cells express- of muscle size. NFB has been suggested to mediate
the effects of TNF in inducing muscle wasting in sepsising the c.a. Foxo3, which cannot be phosphorylated.
and cancer (Li et al., 2003) and AKT has been reportedFurther studies explored the effects of these treat-
to activate NFB by triggering IB degradation (Israel,ments on the activity of the atrogin-1 promoter. To pre-
2000). We therefore used adenoviral constructs to ex-pare an atrogin-1 reporter gene construct, we cloned
press components of the NFB pathway in myotubes3.5 kb of the mouse atrogin-1 5 untranslated region
and assayed the effects on atrogin-1 expression. Nobehind the firefly luciferase gene (3.5AT1) and then made
changes in the levels of atrogin-1 mRNA were seen upona further truncation of this region to create a 1.0 kb
expression of either a constitutively active form of thepromoter fragment (1.0AT1). Foxo3 stimulated the activ-
NFB-inducing kinase (c.a. NIK), which activates IKKity of both the promoters (Figure 3B). However, the 3.5
and causes IB degradation, or c.a. IB, which resistskb construct showed greater activity than the 1.0 kb
degradation (Figure 4A). Thus, activation of NFB orconstruct, presumably because 3.5AT1 contains 14 po-
maintaining NFB inactive, complexed with IB, did nottential forkhead binding sites while 1.0AT1 contains only
influence atrogin-1 expression.3 (see below, Figure 6C). These findings indicate that
Since inhibition of GSK3by AKT leads to hypertrophyFoxo3 increases atrogin-1 mRNA content through en-
of myotubes (Rommel et al., 2001), activation of GSK3hanced transcription rather than some indirect effect on
might be a possible mechanism contributing to atrophy.mRNA stability.
c.a. GSK3 induced a small but reproducible increase
in atrogin-1 expression. However, a d.n. GSK3 mutantFoxo3 Reduces Myotube Size
had no effect (Figure 4A). Additional experiments dem-Since atrogin-1 induction plays a key role in atrophy
onstrated that altering the activity of NFB or GSK3and is regulated by Foxo factors, we tested whether
did not influence the induction of atrogin-1 by Dex (seeactivation of Foxo3 might trigger “atrophy” in vitro. Myo-
Supplemental Figure S1 available at http://www.cell.tubes were infected with adenoviral vectors expressing
com/cgi/content/full/117/3/399/DC1). In contrast to c.a.various forms of Foxo3 four days after differentiation,
NIK or c.a. IB, expression of Foxo3 and to a muchwhen the myotubes are of constant size (data not shown)
lesser extent, GSK3, activated the atrogin-1 promoter
and myoblast fusion no longer occurs (Rommel et al.,
(Figure 4B). These findings together argue against a
2001). Morphological examination of the cells express-
major role of GSK3 or NFB in regulating atrogin-1 ex-
ing c.a. Foxo3 for 48 hr demonstrated a 50% reduction in pression.
mean myotube diameter compared with those expressing
only GFP, which did not change diameter during this AKT also Suppresses atrogin-1 Expression
time (Figure 3C). Furthermore, when the myotubes were in Adult Skeletal Muscle
infected with a dominant-negative adenoviral construct In order to determine whether the IGF-1/AKT/Foxo path-
for Foxo3 (d.n. FOXO3A) which lacks the transactivation way also reduces atrogin-1 expression and influences
domain, there was a 30% decrease in the expression fiber size in adult muscle, as it does in cultured myo-
of atrogin-1 and the induction of atrogin-1 mRNA by tubes, we transfected adult mouse skeletal muscles by
Dex was prevented (Figure 3D). Alone, the d.n. Foxo3 electroporation with 3.5AT1 and with constructs ex-
had no effect on myotube size, but it blocked completely pressing members of the AKT/Foxo pathway. We have
the decrease in cell size caused by Dex. These findings used this technique previously to introduce multiple
demonstrate a key role of dephosphorylated Foxo3 in DNA constructs into muscle fibers in mice (Pallafacchina
both the transcription of atrogin-1 and in the myotube et al., 2002). Initial experiments demonstrated that the
atrophy caused by glucocorticoids. electroporated atrogin-1 reporter was regulated in a
similar way as the endogenous atrogin-1 gene since 24
Other Targets of AKT Have Little Effect hr after food deprivation, extracts of muscles trans-
on atrogin-1 Expression fected with the atrogin-1 reporter contained 3–4-fold
To learn if other AKT-regulated proteins also influence more luciferase activity than extracts of muscles of fed
atrogin-1 expression, we examined several AKT targets animals, and the endogenous atrogin-1 gene was in-
duced as shown by in situ hybridization (Figure 5A).that have been proposed to play a role in the regulation
Foxo and Muscle Atrophy
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To test if AKT activation suppresses atrogin-1 expres- edly reduced at both times (p 0.01), this 35% decrease
in cross-sectional area after eight days resembles thesion in these muscles, we cotransfected 3.5AT1 with
HA-tagged c.a. AKT (Brunet et al., 1999). This active atrophy in tibialis anterior one week after denervation
(Bodine et al., 2001b). These changes in fiber size wereform of AKT reduced the atrogin-1 promoter activity to
10% of its normal level, and completely blocked the even more dramatic at 14 days, when c.a. FOXO3A-
positive fibers contained minimal cytoplasm, while thelarge increase in promoter activity that occurs after food
deprivation (Figure 5A). Furthermore, in the muscles peripheral nuclei appeared normal, and no evidence for
apoptosis was noted by TUNEL (data not shown). Atfrom food-deprived mice, the AKT-transfected fibers
contained little atrogin-1 message by in situ hybridiza- this time, cross-sectional area of 1200 fibers from nine
muscles was reduced by 58%. Since overexpressiontion, while the surrounding untransfected fibers con-
tained high levels of atrogin-1 mRNA (Figure 5A). Thus, of atrogin-1 alone does not cause myotube or muscle
atrophy (M.S., C.S., and S.H.L., unpublished data) theseAKT activity is a key factor suppressing atrogin-1 ex-
pression in vivo and can even block its induction in findings suggest that Foxo3 also induces other atrophy-
related transcriptional changes that lead to the en-fasting.
hanced protein breakdown necessary to account for
such marked fiber shrinkage.Foxo Activates the atrogin-1 Promoter in Mouse
Muscle during Fasting
Subsequent studies examined whether Foxo3 had simi- Forkhead Binding Sites Are Located at 5 End
lar effects on atrogin-1 expression in adult mouse mus- of the atrogin-1 Gene
cles. After transfection, HA-tagged wild-type Foxo3 was Since forkhead factors appear to catalyze transcription
found by immunohistochemistry in both nuclei and cyto- of the atrogin-1 promoter, we made a series of promoter
plasm, while the HA-tagged c.a.FOXO3A mutant was truncations to define the important binding sites (Figure
present exclusively in nuclei (Figure 5B). Transfection 6A), and then transfected adult mouse muscles by elec-
of both 3.5AT1 and these Foxo3 constructs showed that troporation with the atrogin-1 reporters with or without
the atrogin-1 promoter was activated 3-fold by wild- constructs expressing c.a. Foxo3. The extent of reporter
type Foxo3 and more than 20-fold by c.a. Foxo3 (Figure induction by Foxo3 appeared to correlate roughly with
5C). To ensure that the increased activity of the atrogin-1 the length of the promoter construct (i.e., presumably
reporter reflected Foxo3 function, the luciferase gene with the presence of multiple forkhead-sensitive regions
driven by 6 Foxo binding sites arrayed in tandem was throughout the 5 untranslated region; Figure 6B). Sur-
used as the reporter (DBE promoter, [DAF-16 Binding prisingly, even the smallest 5 atrogin-1 fragment, which
Elements]) (Figure 5C). This construct was activated to reduced the basal activity of the promoter, responded
a similar extent by coexpression of wild-type or c.a. to Foxo3. A detailed analysis of that short sequence
Foxo3 as was the atrogin-1 promoter. Furthermore, the revealed two potential forkhead binding sites, one lo-
fibers overexpressing Foxo3 also showed increased cated just past the transcription start site (Foxo1, 2),
atrogin-1 mRNA levels as detected by in situ hybridiza- and a second partially overlapping the putative TATA
tion (Figure 5D). box at 94 relative to the transcription start site (Foxo2)
To test whether Foxo also induces atrogin-1 in atro- (Figure 6C). The ability of forkhead to bind to these sites
phying muscle during fasting, we expressed an RNAi was tested in an electrophoretic mobility shift assay
containing a region that blocks the function of both using a purified forkhead fusion protein (Figure 6D).
Foxo1 and Foxo3. Electroporation of the RNAi com- FoxoGST, bound to a known forkhead site from the
pletely prevented the induction of the atrogin-1 pro- IGFBP1 promoter. A 100-fold molar excess of unlabeled
moter in these muscles 24 hr after food deprivation (Fig- IGFBP1 oligonucleotide prevented formation of the
ure 5E). In myotubes, this RNAi construct reduced Foxo1 FoxoGST-IGFBP1 complex. Formation of this complex
and 3 levels by more than 50%. By contrast, a control was also markedly reduced by an unlabeled oligonucle-
RNAi (against GFP) did not affect the activation of the otide containing one of the putative forkhead binding
atrogin-1 promoter. In addition, RNAi against unique sites in the atrogin-1 promoter, ATAAATA (AT Foxo 1).
Foxo1 and Foxo3 sequences also partially prevented By contrast, a mutated version of this site, ATCACTA (AT
activation of the atrogin-1 reporter (see Supplemental Foxo 1mut), and an unrelated oligonucleotide containing
Figure S2 available on Cell website) Thus, Foxo factors an SP1 binding site, did not prevent complex formation.
are critical in the induction of atrogin-1 during fasting FoxoGST also bound to the oligonucleotide containing
(Figure 5E) and Foxo inactivation can account for the the Foxo1 site but did not bind to the mutated version.
inhibition of this response by AKT. Finally, in a competition assay, increasing amounts of
the unlabeled AT Foxo 1 oligonucleotide, but not of the
mutated version, were able to block FoxoGST-AT Foxo 1Foxo3 Causes Marked Atrophy of Adult
Skeletal Muscle complex formation. These results confirm that forkhead
factors can bind directly to the atrogin-1 5 untranslatedTo test if Foxo3 not only promotes atrogin-1 transcrip-
tion but might also trigger the entire atrophy program, region close to both the putative TATA box and the
initiation site of transcription. While unusual, there arewe transfected HA-tagged c.a. FOXO3A into mouse tibi-
alis anterior muscle, and measured fiber size 8 and 14 other examples when elements involved in transcrip-
tional regulation are found in untranslated regions down-days later. Muscle fibers expressing c.a. FOXO3A (Fig-
ure 5F), were much smaller than the untransfected sur- stream the TATA box (Gilley et al., 2003).
Finally, we investigated whether both forkhead bind-rounding fibers. Mean cross-sectional area, determined
in more than 1800 fibers from eight muscles, was mark- ing sites in the short 0.4 kb fragment of the promoter
Cell
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Figure 5. AKT Suppresses and Foxo Stimulates atrogin-1 Expression and Foxo Activation Causes Marked Atrophy of Mouse Muscle Fibers
(A) AKT prevents induction of atrogin-1 expression by fasting. Left image: mouse tibialis anterior muscles were transfected by electroporation with
the 3.5AT1 and pRL-TK. Seven days later, the mice were fed or fasted and then sacrificed. Firefly and Renilla luciferase activity was measured in
muscle extracts. In situ hybridization on sections from muscles of fed and fasted mice (left image, insert). Scale bar is equal to 60 m. Middle
image: muscles were cotransfected with 3.5AT1, pRL-TK, and either c.a. HA-AKT or the parent vector. Seven days later, the mice were fasted for
24 hr and sacrificed. Firefly/Renilla luciferase activity was measured. Right image: serial cross-sections of these transfected muscles were processed
for immunofluorescence with anti-HA antibody or for in situ hybridization with an atrogin-1 antisense probe. Scale bar is equal to 50 m.
(B) Nuclear localization of c.a. FOXO3A. Sections of adult tibialis anterior muscles transfected with c.a. FOXO3A or FOXO3A were prepared and
visualized with anti-HA antibodies (for Foxo) and Hoechst staining (for nuclei) four days after infection. Images were merged to demonstrate
colocalization. Scale bars are equal to 20 m for c.a. FOXO3A and 30 m for FOXO3A.
(C) Foxo3 activates the atrogin-1 promoter in transfected muscle fibers. Muscles were cotransfected with 3.5AT1, pRL-TK, and with either FOXO3A
or c.a. FOXO3A as described above. Similarly, a Foxo reporter (DBE promoter) was transfected in place of the atrogin-1 reporter. Luciferase activity
was measured four days after transfection.
(D) Atrogin-1 mRNA is increased in muscle fibers overexpressing Foxo3. Cross-sections of tibialis anterior muscle transfected with c.a. FOXO3A
were processed for immunofluorescence with anti-HA antibody or for in situ hybridization for atrogin-1 four days after transfection. Atrogin-1
transcripts are increased in Foxo3 overexpressing fibers, in close proximity to the Foxo3-positive nuclei (arrow) Scale bar is equal to 40 m.
(E) siRNA-mediated knockdown of Foxo1-3 inhibits atrogin-1 promoter activity during fasting. Left image: adult skeletal muscle was cotransfected
with pSUPER-vectors, pRL-TK and 3.5AT1. Seven days later, the mice were fasted and sacrificed. Firefly/renilla luciferase activity was measured
as above. Right image: Foxo1 and 3 protein level detected by immunoblot in myotubes.
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are necessary for the activation by Foxo3. We used other atrophy-related muscle-specific E3. However, it
will be important to determine which of the other recentlysite-directed mutagenesis to introduce into the 0.4 kb
identified atrogenes are controlled directly or indirectlyreporter, mutations in Foxo1, and both Foxo1 and Foxo2
by Foxo.(Figure 6E). Adult muscles were transfected with the
During atrophy, Foxo 1- and 3-dependent transcrip-mutated reporters and c.a. Foxo3, and luciferase activity
tion appears to be activated by two mechanisms: (1)determined in muscle extracts four days later. The single
their mRNA levels rise, presumably through increasedmutation in Foxo1 reduced Foxo3-mediated activation
transcription (Lecker et al., 2004), and (2) these factorsby 70% below the level with the 0.4 kb atrogin-1 pro-
are hypo- or dephosphorylated due to the reduction inmoter, and almost no activation was observed with the
AKT activity (and/or perhaps by action of a phospha-double-mutant lacking both binding sites. These experi-
tase). Amongst the genes most strongly induced in ourments show by a combination of approaches that Foxo3
microarray analyses of atrophy due to fasting, diabetes,binds to the atrogin-1 promoter and activates its tran-
uremia, and cancer (Jagoe et al., 2002, Lecker et al.,scription.
2004) are PDK4, p21, Gadd45, 4E-BP1, all of which can
be controlled by Foxo factors (Nakae et al., 2003; PuigDiscussion
et al., 2003; Tran et al., 2003). Moreover, Foxo family
members have been recently implicated in the develop-Foxo and Atrophy
ment of insulin resistance (Nakae et al., 2002), a promi-The present studies have provided several important
nent feature of muscles in all of these catabolic states.new insights concerning the control of muscle fiber size
Resistance to insulin should also reduce the inhibitionand the mechanisms of atrophy. Specifically, we have
of expression of atrogin-1, MuRF-1, and other atro-shown that: (1) in normal, growing myotubes and adult
genes, as well as the inhibition of protein degradationmuscle fibers, the IGF-PI3K-AKT pathway suppresses
by insulin and IGF-1. In these atrophying muscles,the expression of the key ubiquitin ligase atrogin-1 by
mRNA for IGF binding protein 5, an enhancer of IGF-1inactivating Foxo factors; (2) activation of Foxo can by
function also decreased (Lecker et al., 2004), which mayitself cause dramatic atrophy of myotubes and mature
additionally contribute to IGF-1 resistance and Foxo ac-muscle fibers; and (3) inhibiting Foxo function reduces
tivation.the induction of atrogin-1 by glucocorticoids in vitro and
In a variety of organisms, AKT and its downstreamby fasting in vivo. Thus, activation of Foxo 3 is both
targets affect muscle size. In Drosophila, the loss of AKTnecessary and sufficient for rapid atrophy, as presum-
leads to smaller organs due to a reduction in cell size
ably is activation of Foxo 1 and 4, since these three
and number (Verdu et al., 1999), and mice deficient in
family members appear to be coordinately regulated. In
AKT1/2 have very little muscle mass (Peng et al., 2003).
muscles atrophying due to fasting, diabetes, uremia, or In addition, overexpression of the Foxo homolog in Dro-
cancer, Foxo 1 and 3 mRNA levels rise (Furuyama et al., sophila, dFoxo, leads to small flies with reduced cell
2003; Lecker et al., 2004). In our two models of myotube numbers and structural changes resembling those in
atrophy, Foxo 1, 3, and 4 appeared to be phosphorylated starvation (Kramer et al., 2003; Puig et al., 2003). How-
and dephosphorylated in a similar manner. It is notewor- ever, final muscle mass is determined by the initial rate
thy that the d.n. FOXO3A constructs used here also of formation and growth of myotubes and subsequently
reduce function of Foxo 1 and 4. by the postnatal hypertrophy of muscle fibers. Both
These experiments are the first to implicate a specific myotube fusion and the net accumulation of proteins
transcription factor in atrophy of any cell and demon- are stimulated by IGF-1 and AKT, and thus may be inhib-
strate an unexpected role for the Foxo family in the ited by Foxo3. In fact, inhibition of Foxo family members
control of muscle cell size. In many cells, transcription by phosphorylation may be required for muscle cell dif-
by Foxo retards cell cycle progression and activates ferentiation and fusion of myoblasts into myotubes (Hri-
apoptosis (Tran et al., 2003). Consequently, to avoid bal et al., 2003). However, the atrophy of adult muscle
causing apoptosis or other problems that are likely when and of myotubes in the models studied here is a distinct
Foxo3 is transduced into myoblasts (Bois and Grosveld, process unrelated to myoblast fusion. In these differenti-
2003), we used viral infection of differentiated myotubes ated myotubes, which are no longer replicating, and in
and gene transfer into adult muscles to analyze the adult muscle where growth is not occurring, Foxo action
effects of Foxo3 in postmitotic tissue where it did not does not affect cell number, and apoptosis is not evident
cause apoptosis. by TUNEL. Instead, Foxo, like disuse atrophy or muscle
To elicit profound atrophy, Foxo factors must stimu- wasting during disease, is causing shrinkage and
late the expression of many atrophy-related genes and marked loss of preexistent cell protein. Furthermore,
enhance protein degradation. Because MuRF-1 is in- it may be misleading to extrapolate from observations
duced by glucocorticoids and suppressed by IGF-1 (Sa- concerning the control of myoblast fusion (e.g., by NFB
check et al., 2004; Stitt et al., 2004) it seems very likely or TNF) to possible mechanisms for atrophy or
cachexia in vivo.that Foxo also transcribes the gene for MuRF-1, the
(F) Foxo3 expression for 8 or 14 days causes marked muscle fiber atrophy. Left images: adult tibialis anterior muscles were transfected with c.a.
FOXO3A and mice were sacrificed after 8 or 14 days. Atrophic fibers expressing c.a. FOXO3A were detected in transverse sections stained with
anti-HA (for Foxo) (asterix in eight day micrograph) For eight days, scale bar is equal to 50 m. For 14 days, scale bar is equal to 20 m. Right
images: frequency histograms showing the distribution of cross-sectional areas (m2) of fibers expressing c.a. FOXO3A for eight days (red bars)
or 14 days (pink bars) and surrounding untransfected fibers (control fibers) (black bars).
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Figure 6. Foxo Binding Sites Are Required for atrogin-1 Promoter Activation by Foxo3
(A) Serial truncations of the atrogin-1 promoter were fused to the firefly luciferase gene.
(B) The atrogin-1 reporters and pRL-TK were transfected into adult muscle in presence or in absence of c.a. FOXO3A as above. Mice were sacrificed
four days after transfection and muscles were assayed for luciferase activity.
(C) The atrogin-1 promoter. Multiple forkhead consensus binding sites are noted by black circles. Potential forkhead binding site (Foxo1) present
in smallest promoter truncation, used in the gel-shift experiment in (D), as well as the mutated version are shown.
(D) Purified FoxoGST protein was tested for binding to double-stranded 32P-labeled oligonucleotides containing the IGFBP1 site, AT Foxo 1 and
AT Foxo 1 mut sites by electrophoretic mobility shift assay as described in Experimental Procedures. Arrow, FoxoGST–oligonucleotide complexes.
Asterix, nonspecific band.
(E) Left image: mutations in the 0.4 kb atrogin-1 luciferase reporter constructs. The two putative Foxo sites are noted by black circles and mutations
by X. Right image: adult muscle were transfected with the atrogin-1 reporters described in the left image together with pRL-TK and c.a. FOXO3A
and luciferase activity measured.
IGF-1 and Insulin Suppress an Atrophy Program program for atrophy constitute important new actions
of these hormones that must contribute in a major wayThe ability of insulin and IGF-1 to suppress the activation
by Foxo of atrogin-1 expression and the transcriptional to their capacity to stimulate muscle growth. While their
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Figure 7. A Summary of the Roles of the IGF-
1/AKT Pathway and Foxo in Muscle Atrophy
(right image) and
Hypertrophy (left image)
Factors and pathways in bold are activated
(see text for details).
ability to stimulate muscle protein synthesis through is decreased by insulin apparently because AKT can
maintain Foxo in an inactive state. Because the atrogin-1activation of PI3K and AKT is widely appreciated, IGF-1
and insulin also reduce expression of atrogin-1 and pro- promoter lacks glucocorticoid-response elements, glu-
cocorticoids must act indirectly by inducing or activatingtein breakdown, especially of myofibrillar proteins, and
this effect correlates with the decreased expression of proteins that stimulate atrogin-1 transcription. The obvi-
ous candidates are Foxo family members. In fact, afteratrogin-1 (Sacheck et al., 2004). Thus, in promoting
growth, IGF-1 and insulin not only enhance overall syn- administration of glucocorticoids, Foxo1 and 3 mRNA
rise in muscle (Furuyama et al., 2003), as occurs in vari-thesis but also suppress proteolysis and the expression
of atrophy-related ubiquitin ligases. Under these ana- ous types of atrophy (Lecker et al., 2004). Foxo members
and glucocorticoids function together in controllingbolic conditions, general protein synthesis rises at the
translational level due to AKT-induced phosphorylation transcription in liver cells (Nakae et al., 2001; Nasrin
et al., 2000). In fasting, when glucocorticoids stimulateand activation of mTOR and S6K, while the phosphoryla-
tion of Foxo factors leaves them inactive in the cytosol. proteolysis and net release of amino acids from muscle,
they enhance the liver’s capacity to convert amino acidsTogether, these adaptations lead to protein accumula-
tion and fiber hypertrophy (Figure 7, left). By contrast, to glucose, and some of these gluconeogenic actions
require Foxo1 and 3 (Nakae et al., 2001). Foxo1 andin catabolic conditions, where IGF-1 and insulin are low
(e.g., fasting or diabetes) and there is resistance to their 3 work as cofactors with glucocorticoids perhaps by
recruiting the p300/CBP/SRC coactivator complex toactions (e.g., cancer, uremia, sepsis, Cushing’s syn-
drome), or after denervation and disuse (Bodine et al., the forkhead binding site (Nasrin et al., 2000). Similarly,
glucocorticoids may promote atrogin-1 expression and2001b), AKT is dephosphorylated and its activity re-
duced below control levels, leading to activation of Foxo atrophy not only by inducing Foxo, but also by recruiting
other factors to act with Foxo1 or 3 on the atrogin-1and to transcription of atrogin-1, MuRF1, and other
genes that promote wasting (e.g., genes for insulin resis- promoter.
Kinases downstream of AKT, including GSK3, as welltance). Consequently, all these states should involve
reduced protein synthesis, because of the dephosphor- as the MEK and calcineurin systems, have been impli-
cated in the regulation of muscle fiber size (Bodine etylation of GSK, mTOR, and S6K. Together, these adapta-
tions lead to a dramatic decrease in cell protein and al., 2001a; Murgia et al., 2000; Musaro et al., 1999).
However, in contrast to AKT, none of these factors weremyofiber size (Figure 7, right).
Glucocorticoids are also required for enhanced prote- found to have direct roles in the regulation of atrogin-1
expression. Our findings with Foxo3 can account for theolysis and muscle wasting in many systemic diseases
(Hasselgren, 1999). The sensitivity of rat muscles and prior observation that inhibition of AKT by a dominant-
negative mutant induces myotube atrophy (Bodine etmyotubes to the catabolic actions of glucocorticoids
Cell
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GFP, and the control -gal adenoviral vectors have all been de-al., 2001b; Pallafacchina et al., 2002). By contrast, the
scribed previously (Kim et al., 2002; Skurk et al., 2004).inability of dominant-negative GSK3 (Supplemental
Figure S1 available on Cell website) or LiCl treatment
Protein Extraction, Western Blotting, RNA Extraction,(data not shown) to inhibit atrogin-1 induction by Dex
and Northern Blot Analysisseems to rule out a major role for GSK3 in this process.
See Supplemental Data available on Cell website.
Atrogin-1 induction also appears to occur independently
of mTOR/S6K since IGF-1 could suppress atrogin-1 ex-
atrogin-1 Promoter Cloningpression even in cells starved for nutrients and serum,
See Supplemental Data available on Cell website.
where there was almost a complete inhibition of mTOR/
S6K (Figure 2A). Most likely, in these starved cells, as
Transient Transfections and Luciferase Assays in Muscle
in fasting in vivo, protein translation decreases through Cell Cultures
mechanisms involving mTOR/S6K and GSK3 de- Myoblasts were transfected with different reporters using Lipofec-
phosphorylation, while the concomitant activation of tamine2000 (Invitrogen) according to the manufacturer’s instruc-
tions. When the cells reached confluence, the medium was shiftedatrogin-1 transcription involves Foxo dephosphoryla-
to differentiation medium to induce myotube formation. After fourtion. Accordingly, inhibition of PI3K (with LY294002,
days, myotubes were infected with adenovirus as described above.dominant-negative AKT, or constitutively active SHIP)
36 hr later, myotubes were lysed and analyzed using the Dual-leads to atrophic myotubes, but inhibition of mTOR with Luciferase reporter assay system (Promega). Detailed experimental
rapamycin does not induce atrophy in culture or in vivo procedures are described in Supplemental Data available on Cell
(Bodine et al., 2001b; Pallafacchina et al., 2002; Rommel website.
et al., 2001).
The proinflammatory cytokine TNF has also been Electrophoretic Mobility Shift Assay (EMSA)
proposed to stimulate muscle atrophy in sepsis and EMSA technique and oligonucleotides are described in Supplemen-
tal Data available on Cell website.certain types of cancer, and in many cells, TNF triggers
activation of the transcription factor NFB (Li et al.,
RNAi in Myotubes2003). Based on its ability to inhibit myoblast differentia-
The siRNA for Foxo1-3 (see below) was cloned into Lentilox RNAition, which is a very different process from atrophy of
vector pLL3.7 (Rubinson et al., 2003) and was cotransfected withadult muscle fiber, NFB had been proposed to be a
the lentivirus packaging mix (ViraPower Packaging Mix, Invitrogen)key factor causing muscle wasting and cachexia (Gut-
into 293FT cells. Supernatant from three 150 cm2 dishes were col-
tridge et al., 2000). Our findings upon transfection of an lected, ultrancentrifuged at 25,000 rpm in SW28 Beckman rotor for
activator of NFB or a dominant-negative IB mutant 1.5 hr, and resuspended in 100 l of cold PBS. C2C12 myoblasts
exclude an important role for NFB or TNF in the con- were infected (50 l virus/9.4 cm2 dish) and differentiated for eight
days. Myotubes were lysed in Trizol and protein level analyzed bytrol of atrogin-1 transcription, although they may pro-
Western blot. At least 70% of myotubes were infected in thesemote wasting by other mechanisms.
experiments.While clearly advancing our understanding of the
mechanisms of atrophy, the present findings have raised
Adult Mouse Skeletal Muscle Transfectionmany important questions concerning the role of differ-
Adult female CD1 mice (28–30 g) were used in all experiments.ent Foxo family members, what genes they transcribe
Tibialis anterior muscles were transfected as described previously
in muscle to trigger atrophy and the precise functions (Murgia et al., 2000). The muscle was isolated through a small hind-
of atrogin-1 and MuRF1 in muscle wasting. While our limb incision, and 25 g of plasmid DNA was injected along the
understanding remains limited, the identification of muscle length. In reporter experiments, 10 g of the expression
vector with 10 g of the 3.5AT1 reporter construct and 5 g of pRL-Foxo3 as a major activator of atrogin-1 expression and
TK vectors were coinjected. Electric pulses were then applied bymuscle atrophy suggests several new approaches for
two stainless steel spatula electrodes placed on each side of thepharmacological interventions to prevent or diminish
isolated muscle belly (50 Volts/cm, 5 pulses, 200 ms intervals). Mus-
this debilitating process. cles were analyzed 4, 8, or 14 days later. No gross or microscopic
evidence for necrosis or inflammation as a result of the transfection
Experimental Procedures procedure was noted. The reporter containing six forkhead binding
sites (DBE promoter) (Furuyama et al., 2000) was generated by liga-
Antibodies and Reagents tion of the following oligonucleotides to NheI-XhoI double digested
See Supplemental Data available on Cell website. pGL3-basic vector. DBE oligonucleotides: 5-TCGAAAGTAAACAAC
TATGTAAACAACTATAAGTAAACAACTATGTAAACAACTATAAGTA
Cell Culture, Adenoviral Infection, and Myotube Analysis AACAACTATGTAAACAAGATC-3 and 5-CTAGGATCTTGTTTACAT
C2C12 mouse myoblasts (ATCC) were cultured in DMEM 10% FCS AGTTGTTTACTTATAGTTGTTTACATAGTTGTTTACTTATAGTTGTT
(ATCC) until the cells reached confluence. The medium was then
TACATAGTTGTTTACTT-3.
replaced with DMEM 2% horse serum (HS) (ATCC) (“differentiation
medium”) and incubated for four days to induce myotube formation
Immunohistochemistry and Fiber Size Measurementsbefore proceeding with experiments. For infection, myotubes were
Mouse muscle fibers expressing HA-tagged proteins were stainedincubated with adenovirus at a multiplicity of infection (MOI) of 250
in cryocross-sections fixed with 4% paraformaldehyde. Immunohis-in differentiation medium for 18 hr, and then medium was replaced.
tochemistry with anti-HA polyclonal antibody (Santa Cruz) was asThe infection efficiency was typically greater than 90%. Myotube
previously described (Pallafacchina et al., 2002). Muscle fiber sizediameter was quantified by measuring a total of 	160 tube diame-
was measured in fibers transfected with the Foxo3 mutant and inters from five random fields at 100
 magnification using IMAGE
an equal number of untransfected fibers from the same musclesoftware (Scion, Frederick, MD) as described (Rommel et al., 2001).
as described elsewhere (Pallafacchina et al., 2002). Fiber cross-All data are expressed as the mean  SEM.
sectional areas were measured using IMAGE software (Scion, Fred-
erick, MD). All data are expressed as the mean SEM. ComparisonAdenoviral Vectors
were made by using the student’s t test, with p 0.05 being consid-The d.n. AKT, the c.a. AKT, the c.a. GSK3, d.n. SK3, c.a. NIK, c.a.
IB, human Foxo3 (FOXO3A), c.a. FOXO3A, d.n. FOXO3A, control ered statistically significant.
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In Situ Hybridization pressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 98,
14440–14445.In situ hybridization was performed as described (Murgia et al.,
2000). An 35S-labeled cRNA probe complementary to the atrogin-1 Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.Y., and Baldwin,
coding region was prepared by in vitro transcription (Roche) using A.S., Jr. (2000). NF-B-induced loss of MyoD messenger RNA: possi-
the full-length mouse atrogin-1 gene in KSBluescript as a template. ble role in muscle decay and cachexia. Science 289, 2363–2366.
Hasselgren, P.O. (1999). Glucocorticoids and muscle catabolism.
RNAi in Adult Skeletal Muscle Curr. Opin. Clin. Nutr. Metab. Care 2, 201–205.
A target finder and design tool (Ambion) was used to identify target
Hribal, M.L., Nakae, J., Kitamura, T., Shutter, J.R., and Accili, D.regions in the mouse Foxo1 and 3 and GFP genes amenable to
(2003). Regulation of insulin-like growth factor-dependent myoblastsiRNA. Foxo1 and 3: 5-GGATAAGGGCGACAGCAAC-3, Foxo1:
differentiation by Foxo forkhead transcription factors. J. Cell Biol.5-CCTGTCGTACGCCGACCTC-3, Foxo3: 5-TGAAGGCACGGG
162, 535–541.CAAGAGC-3, GFP: 5-GCAAGCTGACCCTGAAGTTC-3. These se-
Imae, M., Fu, Z., Yoshida, A., Noguchi, T., and Kato, H. (2003).quences were incorporated into 64 bp self-annealing oligonucleo-
Nutritional and hormonal factors control the gene expression oftides (Brummelkamp et al., 2002), synthesized and cloned into BglII-
FoxOs, the mammalian homologues of DAF-16. J. Mol. Endocrinol.HindIII double-digested pSUPER vector. Adult skeletal muscle was
30, 253–262.cotransfected with 30 g of the pSUPER vector along with 10 g
of the 3.5 kb atrogin-1-firefly luciferase reporter construct and 5 g Israel, A. (2000). The IKK complex: an integrator of all signals that
of pRL-TK vectors as above described. Seven days after transfec- activate NF-B? Trends Cell Biol. 10, 129–133.
tion, the mice were fasted for 24 hr and sacrificed. Jagoe, R.T., and Goldberg, A.L. (2001). What do we really know
about the ubiquitin-proteasome pathway in muscle atrophy? Curr.
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